Get the Stockscreener App
10.18
6.25%
-0.698
Celcuity Inc stock is traded at $10.18, with a volume of 23,243.
It is down -6.25% in the last 24 hours and down -19.17% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$10.88
Open:
$10.85
24h Volume:
23,243
Relative Volume:
0.09
Market Cap:
$401.74M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-3.7993
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+2.21%
1M Performance:
-19.17%
6M Performance:
-31.91%
1Y Performance:
-43.20%
1-Day Range:
$10.20
$11.00
1-Week Range:
$9.50
$11.00
52-Week Range:
$8.75
$22.19
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
10.23 | 401.74M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.49 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.33 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.00 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.63 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights By Investing.com - Investing.com South Africa
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights - Investing.com Canada
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus.com
Rhumbline Advisers Boosts Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
(CELC) Technical Data - Stock Traders Daily
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.17 - Defense World
Celcuity, Inc. to Host Earnings Call - ACCESS Newswire
New York State Common Retirement Fund Purchases 3,682 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - Quantisnow
(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Celcuity stock touches 52-week low at $10.35 amid market challenges - Investing.com India
Celcuity stock touches 52-week low at $10.35 amid market challenges By Investing.com - Investing.com South Africa
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - The Manila Times
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January - MarketBeat
Celcuity Set to Join Russell 2000 and 3000 Indexes - ACCESS Newswire
Celcuity’s High-Stakes Oncology Bet Is Underappreciated (NASDAQ:CELC) - Seeking Alpha
Q1 Earnings Forecast for Celcuity Issued By Leerink Partnrs - MarketBeat
Bleakley Financial Group LLC Acquires Shares of 11,159 Celcuity Inc. (NASDAQ:CELC) - Defense World
Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat
Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - MarketBeat
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
Celcuity Inc. (NASDAQ:CELC) Receives $30.17 Consensus Price Target from Brokerages - Defense World
Scorpion stinger bringer of more PI3Kα inhibitor deals? - BioWorld Online
JPMorgan Chase & Co. Sells 11,612 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference - ACCESS Newswire
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates - ACCESS Newswire
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer - ACCESS Newswire
When (CELC) Moves Investors should Listen - Stock Traders Daily
Jefferies lifts Celcuity stock target to $33, maintains Buy rating - MSN
Jefferies lifts Celcuity stock target to $33, maintains Buy rating By Investing.com - Investing.com Australia
Celcuity Closes $100 Million Private Placement - ACCESS Newswire
Celcuity Inc. Announces $50 Million Private Placement - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Buys 71,006 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Analysts - Defense World
Celcuity Inc. (NASDAQ:CELC) Holdings Raised by Barclays PLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Bought by Barclays PLC - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Brokerages - MarketBeat
Analyzing Celcuity (NASDAQ:CELC) and CannLabs (OTCMKTS:CANL) - Defense World
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celcuity Inc Stock (CELC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Buller Richard E | Director |
Oct 23 '24 |
Sale |
16.25 |
350 |
5,688 |
6,681 |
| Buller Richard E | Director |
Aug 23 '24 |
Sale |
16.95 |
350 |
5,932 |
7,031 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):